Induction of IP-10/CXCL10 secretion as an immunomodulatory effect of low-dose adjuvant interferon-alpha during treatment of melanoma

Immunobiology

Volumn 215, Issue 2, 2010, Pages 113-123

  Mohty, Anne Marie ^a   Grob, Jean Jacques ^b   Mohty, Mohamad ^a   Richard, Marie Aleth ^b   Olive, Daniel ^a   Gaugler, Béatrice ^a  

^a INSTITUT PAOLI CALMETTES   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

Author keywords

Antigen presenting cells; Interferon alpha; IP 10 CXCL10; Melanoma; T lymphocyte sub populations

Indexed keywords

ALPHA2B INTERFERON; CD14 ANTIGEN; CD16 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEGINTERFERON ALPHA2B;

ADULT; AGED; ANTIGEN PRESENTING CELL; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LOW DRUG DOSE; MALE; MELANOMA; MULTICENTER STUDY; PERIPHERAL LYMPHOCYTE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T CELL DEPLETION;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ANTIGENS, CD3; CHEMOKINE CXCL10; COHORT STUDIES; FEMALE; FRANCE; HUMANS; IMMUNOMODULATION; INTERFERON ALFA-2B; LYMPHOCYTE COUNT; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; POLYETHYLENE GLYCOLS; PYRIMIDINONES; RECEPTORS, CXCR3; SKIN NEOPLASMS; T-LYMPHOCYTE SUBSETS; THIAZOLES;

EID: 71849085783     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2009.03.008     Document Type: Article

References (51)

1. de Baey A., Mende I., Riethmueller G., and Baeuerle P.A. Phenotype and function of human dendritic cells derived from M-DC8(+) monocytes. Eur. J. Immunol. 31 (2001) 1646
2. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245
3. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., Pulendran B., and Palucka K. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18 (2000) 767
4. Belardelli F., and Gresser I. The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol. Today 17 (1996) 369
5. Belardelli F., Vignaux F., Proietti E., and Gresser I. Injection of mice with antibody to interferon renders peritoneal macrophages permissive for vesicular stomatitis virus and encephalomyocarditis virus. Proc. Natl. Acad. Sci. USA 81 (1984) 602
6. Bendriss-Vermare N., Burg S., Kanzler H., Chaperot L., Duhen T., de Bouteiller O., D'Agostini M., Bridon J.M., Durand I., Sederstrom J.M., Chen W., Plumas J., Jacob M.C., Liu Y.J., Garrone P., Trinchieri G., Caux C., and Briere F. Virus overrides the propensity of human CD40L-activated plasmacytoid dendritic cells to produce Th2 mediators through synergistic induction of IFN-{gamma} and Th1 chemokine production. J. Leukoc. Biol. 78 (2005) 954
7. Blackwell S.E., and Krieg A.M. CpG-A-induced monocyte IFN-gamma-inducible protein-10 production is regulated by plasmacytoid dendritic cell-derived IFN-alpha. J. Immunol. 170 (2003) 4061
8. Blanco P., Palucka A.K., Gill M., Pascual V., and Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 294 (2001) 1540
9. Brombacher F., Kastelein R.A., and Alber G. Novel IL-12 family members shed light on the orchestration of Th1 responses. Trends Immunol. 24 (2003) 207
10. Cella M., Jarrossay D., Facchetti F., Alebardi O., Nakajima H., Lanzavecchia A., and Colonna M. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med. 5 (1999) 919
11. Di Pucchio T., Pilla L., Capone I., Ferrantini M., Montefiore E., Urbani F., Patuzzo R., Pennacchioli E., Santinami M., Cova A., Sovena G., Arienti F., Lombardo C., Lombardi A., Caporaso P., D'Atri S., Marchetti P., Bonmassar E., Parmiani G., Belardelli F., and Rivoltini L. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res. 66 (2006) 4943
12. Dufour J.H., Dziejman M., Liu M.T., Leung J.H., Lane T.E., and Luster A.D. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J. Immunol. 168 (2002) 3195
13. Dzionek A., Fuchs A., Schmidt P., Cremer S., Zysk M., Miltenyi S., Buck D.W., and Schmitz J. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J. Immunol. 165 (2000) 6037
14. Eggermont A.M., Suciu S., Santinami M., Testori A., Kruit W.H., Marsden J., Punt C.J., Sales F., Gore M., Mackie R., Kusic Z., Dummer R., Hauschild A., Musat E., Spatz A., and Keilholz U. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372 (2008) 117
15. Gilliet M., and Liu Y.J. Generation of human CD8T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J. Exp. Med. 195 (2002) 695
16. Grob J.J., Dreno B., de la Salmoniere P., Delaunay M., Cupissol D., Guillot B., Souteyrand P., Sassolas B., Cesarini J.P., Lionnet S., Lok C., Chastang C., and Bonerandi J.J. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 351 (1998) 1905
17. Guillot B., Portales P., Thanh A.D., Merlet S., Dereure O., Clot J., and Corbeau P. The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment. Br. J. Dermatol. 152 (2005) 690
18. Hilkens C.M., Schlaak J.F., and Kerr I.M. Differential responses to IFN-alpha subtypes in human T cells and dendritic cells. J. Immunol. 171 (2003) 5255
19. Kaser A., Deisenhammer F., Berger T., and Tilg H. Interferon-beta 1b augments activation-induced T-cell death in multiple sclerosis patients. Lancet 353 (1999) 1413
20. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., Smith T.J., Borden E.C., and Blum R.H. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14 (1996) 7
21. Kirkwood J.M., Moschos S., and Wang W. Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations. Clin. Cancer Res. 12 (2006) 2331s
22. Lapenta C., Santini S.M., Logozzi M., Spada M., Andreotti M., Di Pucchio T., Parlato S., and Belardelli F. Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha. J. Exp. Med. 198 (2003) 361
23. Lapenta C., Santini S.M., Spada M., Donati S., Urbani F., Accapezzato D., Franceschini D., Andreotti M., Barnaba V., and Belardelli F. IFN-alpha-conditioned dendritic cells are highly efficient in inducing cross-priming CD8(+) T cells against exogenous viral antigens. Eur. J. Immunol. 36 (2006) 2046
24. Liu Y.J. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 23 (2005) 275
25. Marrack P., Kappler J., and Mitchell T. Type I interferons keep activated T cells alive. J. Exp. Med. 189 (1999) 521
26. Mohty M., Jarrossay D., Lafage-Pochitaloff M., Zandotti C., Briere F., de Lamballeri X.N., Isnardon D., Sainty D., Olive D., and Gaugler B. Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment. Blood 98 (2001) 3750
27. Mohty M., Vialle-Castellano A., Nunes J.A., Isnardon D., Olive D., and Gaugler B. IFN-alpha skews monocyte differentiation into Toll-like receptor 7-expressing dendritic cells with potent functional activities. J. Immunol. 171 (2003) 3385
28. Moser B., Wolf M., Walz A., and Loetscher P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol. 25 (2004) 75
29. Paquette R.L., Hsu N.C., Kiertscher S.M., Park A.N., Tran L., Roth M.D., and Glaspy J.A. Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J. Leukoc. Biol. 64 (1998) 358
30. Parlato S., Santini S.M., Lapenta C., Di Pucchio T., Logozzi M., Spada M., Giammarioli A.M., Malorni W., Fais S., and Belardelli F. Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood 98 (2001) 3022
31. Pfeffer L.M., Dinarello C.A., Herberman R.B., Williams B.R., Borden E.C., Bordens R., Walter M.R., Nagabhushan T.L., Trotta P.P., and Pestka S. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res. 58 (1998) 2489
32. Pflanz S., Timans J.C., Cheung J., Rosales R., Kanzler H., Gilbert J., Hibbert L., Churakova T., Travis M., Vaisberg E., Blumenschein W.M., Mattson J.D., Wagner J.L., To W., Zurawski S., McClanahan T.K., Gorman D.M., Bazan J.F., de Waal Malefyt R., Rennick D., and Kastelein R.A. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 16 (2002) 779
33. Randolph G.J., Beaulieu S., Lebecque S., Steinman R.M., and Muller W.A. Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking. Science 282 (1998) 480
34. Randolph G.J., Sanchez-Schmitz G., Liebman R.M., and Schakel K. The CD16(+) (FcgammaRIII(+)) subset of human monocytes preferentially becomes migratory dendritic cells in a model tissue setting. J. Exp. Med. 196 (2002) 517
35. Rissoan M.C., Soumelis V., Kadowaki N., Grouard G., Briere F., de Waal Malefyt R., and Liu Y.J. Reciprocal control of T helper cell and dendritic cell differentiation. Science 283 (1999) 1183
36. Robinson D.S., and O'Garra A. Further checkpoints in Th1 development. Immunity 16 (2002) 755
37. Rogge L., D'Ambrosio D., Biffi M., Penna G., Minetti L.J., Presky D.H., Adorini L., and Sinigaglia F. The role of Stat4 in species-specific regulation of Th cell development by type I IFNs. J. Immunol. 161 (1998) 6567
38. Sabel M.S., and Sondak V.K. Pros and cons of adjuvant interferon in the treatment of melanoma. Oncologist 8 (2003) 451
39. Sanchez-Torres C., Garcia-Romo G.S., Cornejo-Cortes M.A., Rivas-Carvalho A., and Sanchez-Schmitz G. CD16+ and CD16- human blood monocyte subsets differentiate in vitro to dendritic cells with different abilities to stimulate CD4+ T cells. Int. Immunol. 13 (2001) 1571
40. Santini S.M., Lapenta C., Logozzi M., Parlato S., Spada M., Di Pucchio T., and Belardelli F. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J. Exp. Med. 191 (2000) 1777
41. Santodonato L., D'Agostino G., Nisini R., Mariotti S., Monque D.M., Spada M., Lattanzi L., Perrone M.P., Andreotti M., Belardelli F., and Ferrantini M. Monocyte-derived dendritic cells generated after a short-term culture with IFN-alpha and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response. J. Immunol. 170 (2003) 5195
42. Schmid D.S., and Rouse B.T. The role of T cell immunity in control of herpes simplex virus. Curr. Top. Microbiol. Immunol. 179 (1992) 57
43. Siegal F.P., Kadowaki N., Shodell M., Fitzgerald-Bocarsly P.A., Shah K., Ho S., Antonenko S., and Liu Y.J. The nature of the principal type 1 interferon-producing cells in human blood. Science 284 (1999) 1835
44. Sun S., Zhang X., Tough D.F., and Sprent J. Type I interferon-mediated stimulation of T cells by CpG DNA. J. Exp. Med. 188 (1998) 2335
45. Takeda A., Hamano S., Yamanaka A., Hanada T., Ishibashi T., Mak T.W., Yoshimura A., and Yoshida H. Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J. Immunol. 170 (2003) 4886
46. Theofilopoulos A.N., Baccala R., Beutler B., and Kono D.H. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu. Rev. Immunol. 23 (2005) 307
47. Vermi W., Bonecchi R., Facchetti F., Bianchi D., Sozzani S., Festa S., Berenzi A., Cella M., and Colonna M. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J. Pathol. 200 (2003) 255
48. Wenzel J., Bekisch B., Uerlich M., Haller O., Bieber T., and Tuting T. Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions. Am. J. Clin. Pathol. 124 (2005) 37
49. Wenzel J., Schmidt R., Proelss J., Zahn S., Bieber T., and Tuting T. Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis. Clin. Exp. Dermatol. 31 (2006) 576
50. Yurkovetsky Z.R., Kirkwood J.M., Edington H.D., Marrangoni A.M., Velikokhatnaya L., Winans M.T., Gorelik E., and Lokshin A.E. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin. Cancer Res. 13 (2007) 2422
51. Zou W., Borvak J., Marches F., Wei S., Galanaud P., Emilie D., and Curiel T.J. Macrophage-derived dendritic cells have strong Th1-polarizing potential mediated by beta-chemokines rather than IL-12. J. Immunol. 165 (2000) 4388